16273-81-7

Upstream product

• 31266-88-3 N-(pyridin-2-ylmethyl)picolinamide 
• 88328-13-6 1-phenyl-N-(2-(pyridin-2-yl)methyl)methanimine 
• 3731-51-9 2-(Aminomethyl)pyridine 

Downstream Products

• 842172-90-1 N-[2-Hydroxy-5-[(R)-1-hydroxy-2-[[2-phenyl-1-(4-pyridinyl)ethyl]amino]ethyl]phenyl]methanesulfonamide 
• 69767-56-2 1-phenyl-3-pyridin-2-yl-isoquinoline 
• 95612-47-8 1-benzyl-3-phenylimidazo<1,5-a>pyridine 
• 95612-52-5 N-methyl-2-(2-phenyl-1-trifluoroacetamidoethyl)pyridinium iodide 
• 95612-51-4 N-methyl-2-(1-benzamido-2-phenylethyl)pyridinium iodide 
• 95612-45-6 N-<2-phenyl-1-(2-pyridyl)ethyl>trifluoroacetamide 
• 69767-93-7 N-<2-phenyl-1-(2-pyridyl)ethyl>benzamide 

Relevant academic research and scientific papers

Manganese/cobalt-catalyzed oxidative C(sp3)-H/C(sp3)-H coupling: A route to α-tertiary β-arylethylamines

Reported herein is an oxidative coupling reaction of an α-C(sp3)-H bond of amine with a benzylic C(sp3)-H bond through Mn or Co catalysis to provide diverse collections of α-tertiary β-arylethylamines. This protocol features an easily installed and removable coordinating activation group, a wide scope of substrates, low-cost metal catalysts, easily available starting materials and synthetic simplicity.

Arylalkyl-amines and -amides having anticonvulsant and neuroprotective properties

There is provided a method of treatment of neurological disorders, such as epilepsy, stroke and cerebral ischaemia, which comprises the administration of a compound of Formula I: STR1 wherein, Ar1 and Ar2, which may be the same or different, independently represent phenyl or phenyl substituted by one or more of amino, nitro, halogen, hydroxy, C1 to 6 alkoxy, C1 to 6 alkyl or cyano; R1 represents hydrogen, C1 to 6 alkyl, C1 to 6 alkoxycarbonyl; R2 represents hydrogen or COCH2 NH2 ; R3 represents hydrogen or C1 to 6 alkyl; in addition, when R2 represents hydrogen either one or both of Ar1 and Ar2 may also represent 2-, 3- or 4-pyridinyl and R1 may also represent trihalomethyl; or a pharmaceutically acceptable salt thereof. Some of the compounds of formula I are novel, and these are also provided, together with pharmaceutical compositions containing the novel compounds.

Solid-liquid phase transfer catalytic synthesis VII: The synthesis of α-substituted-2-pyridylmethylamine via the alkylation of benzaldehyde imine

The anion derived from the benzaldehyde imine 2 reacts with alkyl halide to form alkylated products 3; Hydrolysis of 3 gives α-alkyl-2 pyridylmethylamine in 34-53% overall yield.